Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
NCT05479045 · Georgetown University · PHASE2 · withdrawn · last registry update 2026-10-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor Decision” | – | Registry record, Georgetown University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab + Tazemetostat Hydrobromide (NCT05353439)
- 2026-11-10Also stopped (terminated): National Cancer Institute (NCI), Pembrolizumab + Tazemetostat Hydrobromide (NCT05353439)
- 2026-11-10Results posted on the registry: BioXcel Therapeutics Inc, Talabostat + Pembrolizumab (NCT03910660)
- 2026-11-10Results posted on the registry: Amgen, acapatamab + Pembrolizumab (NCT03792841)
- 2026-11-10Also stopped (terminated): Amgen, acapatamab + Pembrolizumab (NCT03792841)
- 2026-11-06Also stopped (suspended): Washington University School of Medicine, Pembrolizumab (NCT04318717)
- 2026-11-05Also stopped (terminated): invoX Pharma Limited, FS120 (NCT04648202)
- 2026-11-04Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., Oxaliplatin + Placebo (NCT07917468)
- 2026-11-04Results posted on the registry: Duke University, Alirocumab and Cemiplimab (NCT05553834)
- 2026-11-04Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nab-paclitaxel + Gemcitabine (NCT04753879)
- 2026-11-04Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against PDCD1 (NCT07915037)
- 2026-11-03Results posted on the registry: Columbia University, Gemcitabine + Cisplatin (NCT06571708)
- 2026-11-03Also stopped (terminated): Columbia University, Gemcitabine + Cisplatin (NCT06571708)
- 2026-11-03Also stopped (terminated): University of Alabama at Birmingham, Pembrolizumab injection (NCT06005818)
- 2026-11-03Also stopped (suspended): National Cancer Institute (NCI), Cemiplimab (NCT06568172)
- 2026-11-02Also stopped (withdrawn): CureVac, CV09070101 mRNA vaccine (CVHNLC) 50 µg + CV09070101 mRNA vaccine (CVHNLC) 100 µg (NCT07073183)
- 2026-11-02Also stopped (withdrawn): Genmab, Petosemtamab + Pembrolizumab (NCT07353957)
- 2026-10-30Also stopped (terminated): Tufts Medical Center, Granulocyte-Macrophage Colony-Stimulating Factor + Pembrolizumab (NCT04856176)
- 2026-10-30Also stopped (withdrawn): Peter MacCallum Cancer Centre, Australia, Olaparib (300 mg BID) + Pembrolizumab (NCT07090369)
- 2026-10-29Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + MK-4830 (NCT04165083)
- 2026-10-29Phase 3 first posted: Sun Yat-sen University, Serplulimab + Fruquintinib (NCT07904156)
- 2026-10-28Results posted on the registry: Immedica Pharma AB, Pegzilarginase + Pembrolizumab (NCT03371979)
- 2026-10-28Also stopped (terminated): Immedica Pharma AB, Pegzilarginase + Pembrolizumab (NCT03371979)
- 2026-10-27Results posted on the registry: Washington University School of Medicine, Olaparib + Pembrolizumab (NCT04643379)
- 2026-10-22Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Carboplatin (NCT03036488)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision